Executive Summary
Across 8 insolvency and restructuring filings, a dominant theme is active NCLT/NCLAT proceedings with 6/8 involving upcoming CoC meetings, shareholder/creditor votes, or hearings, signaling potential resolution catalysts amid ongoing CIRP for most. Embassy Developments stands out as the sole operational outlier with robust Q4 FY26 pre-sales at ₹2,632 crore (+89% QoQ, +128% YoY FY26 total), collections +39% QoQ, and no debt impact despite IBC Stage 1 shift, contrasting negative sentiments in pharma (Remedium, Kopran) and infra (MEP). Negative developments include director non-cooperation in Remedium and RP replacement in Educomp, while schemes of arrangement progress in Gabriel, Kopran, and TVS. Portfolio-level, 4/8 filings show neutral sentiment with procedural advances, but 3/8 negative highlight stalled CIRPs; no YoY/QoQ deteriorations beyond claims verification gaps (Remedium: ₹412cr pending). Market implications favor monitoring resolution timelines for short-term volatility, with Embassy offering relative strength in real estate distress.
Tracking the trend? Catch up on the prior India MCA Insolvency Liquidation Filings digest from April 03, 2026.
Investment Signals(10)
- Embassy Developments↓(BULLISH)▲
Record Q4 FY26 pre-sales ₹2,632cr (+89% QoQ), FY26 ₹4,631cr (+128% YoY), Q4 collections ₹577cr (+39% QoQ) despite IBC Stage 1 and stayed NCLT order, operations unaffected
- Remedium Lifecare↓(BEARISH)▲
CIRP claims ₹1,238cr with only ₹822cr admitted (66% acceptance), ₹234cr govt dues mostly admitted but directors non-cooperative, CoC meet Apr 14
- Future Enterprises↓(BEARISH)▲
41st CoC meeting Apr 13 under RP Avil Menezes (valid to Jun 2027), no outcomes disclosed signaling prolonged CIRP
- TVS Holdings↓(NEUTRAL)▲
NCLT-directed equity shareholder meeting corrected to Apr 24, scheme progress intact per XBRL/newspapers
- Gabriel India↓(BULLISH)▲
Final NCLT hearing advertised Apr 10 for amalgamation/demerger scheme (Anchemco into Asia Investments, demerger to Gabriel), per Mar 24 order
- MEP Infrastructure↓(BEARISH)▲
22nd CoC meeting Apr 9 post 2024 CIRP start, moratorium ongoing with no outcomes/positive developments
- Kopran↓(BULLISH)▲
NCLT Apr 9 order directs equity/secured/unsecured creditor meetings for Kopran Labs merger, advancing scheme
- Educomp Solutions↓(BEARISH)▲
NCLT Apr 8 RP replacement (Kamal Jadwani for Mahender Khandelwal), no board, ongoing CIRP stall
- Embassy vs Peers(BULLISH)▲
+128% YoY pre-sales FY26 vs no growth metrics in 7/8 peers under CIRP, financially sound guarantor exposure only ₹370cr
- Remedium Claims Trend(BEARISH)▲
₹412cr (33%) claims under verification/not admitted QoQ from CIRP start Mar 17, operational creditors ₹82cr rejected
Risk Flags(8)
- Remedium/Director Non-Cooperation↓[HIGH RISK]▼
Suspended directors failed to hand over control/records to IRP Rajesh Jhunjhunwala, delaying CIRP post Mar 17 NCLT order
- MEP Infrastructure/Prolonged CIRP↓[HIGH RISK]▼
22nd CoC meeting Apr 9, 2+ years since Mar 2024 NCLT, moratorium persists with no resolution
- Educomp/RP Instability↓[HIGH RISK]▼
NCLT-ordered RP switch Apr 8 to Kamal Jadwani, prior caretaker Mahender Khandelwal replaced amid no board
- Embassy Developments/ASM Escalation↓[MEDIUM RISK]▼
Shift to IBC Stage 1 (weekly trading) from Stage 0 due to >30% price variation, stayed NCLT Dec 2025 order
- Remedium/Claims Dispute↓[MEDIUM RISK]▼
₹412cr claims pending verification (govt ₹3cr, ops ₹82cr rejected), total ₹1,238cr vs admitted ₹822cr
- Future Enterprises/Meeting Frequency↓[MEDIUM RISK]▼
41st CoC signals extended distress, no financial updates in ongoing CIRP
- MEP vs Peers[HIGH RISK]▼
No operational metrics 2 years into CIRP vs Embassy's +89% QoQ growth, negative sentiment only
- Educomp/Operational Vacuum↓[MEDIUM RISK]▼
New RP to manage all affairs sans board, referencing stalled Mar 2026 updates
Opportunities(8)
- Embassy/NCLAT Hearing↓(OPPORTUNITY)◆
Stay on ₹370cr guarantor CIRP admission holds, operations sound with +128% YoY pre-sales; resolution Apr 17 could lift ASM
- Gabriel/Scheme Final Hearing↓(OPPORTUNITY)◆
Amalgamation/demerger ads Apr 10 per Mar 24 NCLT, potential restructuring value unlock via Asia Investments
- Kopran/Merger Meetings↓(OPPORTUNITY)◆
NCLT Apr 9 directs creditor/shareholder votes for Kopran Labs absorption, scheme advancement post Mar 2025 filing
- TVS Holdings/Shareholder Vote↓(OPPORTUNITY)◆
NCLT Mar 18 scheme meeting Apr 24, error corrected but documents intact for approval
- Remedium/CoC First Meeting↓(OPPORTUNITY)◆
Apr 14 debut CoC under IRP could admit more claims (currently 66%), potential plan momentum
- Future Enterprises/41st CoC↓(OPPORTUNITY)◆
Apr 13 meeting under extended RP mandate to Jun 2027, watch for resolution progress in retail distress
- Embassy/Operational Outperformance↓(OPPORTUNITY)◆
FY26 collections ₹1,721cr amid IBC tag, relative to peers' CIRP stalls
- Kopran vs Pharma Peers(OPPORTUNITY)◆
Scheme progress vs Remedium's negative CIRP, NCLT order publicly available for diligence
Sector Themes(5)
- Frequent CoC Milestones◆
4/8 filings (Future 41st Apr13, Remedium 1st Apr14, MEP 22nd Apr9) show active creditor committees, implying resolution push but prolonged CIRPs (avg 2+ yrs for MEP/Future) [Prolonged distress, monitor outcomes]
- Scheme of Arrangement Progress◆
4/8 (Gabriel, TVS, Kopran, implied others) with NCLT-directed meetings/hearings Apr24-Apr, neutral sentiment vs 3/8 negative [Restructuring alpha in auto/pharma]
- RP/Leadership Changes◆
2/8 (Educomp switch Apr8, Remedium non-coop) highlight governance risks in education/pharma CIRP, no insider data but stalled handovers [Heightened execution risk]
- Real Estate Resilience◆
Embassy sole with metrics (+89% QoQ pre-sales) vs infra MEP's silence, mixed sentiment but operations unaffected [Outlier growth in distress]
- Claims Verification Gaps◆
Remedium 33% claims pending (₹412cr), potential for further rejections impacting recoveries [Creditor recovery downside]
Watch List(8)
Stay on CIRP admission, no adjournments; outcome could exit IBC Stage 1 [Apr 17, 2026]
Claims admission progress, director handover issues [Apr 14, 2026]
Potential CIRP updates in extended proceedings [Apr 13, 2026]
NCLT scheme approval vote [Apr 24, 2026]
Amalgamation/demerger scheme resolution post Apr 10 ads [TBD post Apr 10, 2026]
Equity/secured/unsecured votes per Apr 9 NCLT for merger [TBD post Apr 9, 2026]
Kamal Jadwani operations, formal order copy awaited [Post Apr 8, 2026]
Post-22nd meeting outcomes in ongoing 2024 CIRP [Upcoming post Apr 9, 2026]
Filing Analyses(8)
10-04-2026
Embassy Developments Limited's equity shares were shifted to IBC Stage 1 under the ASM Framework effective April 10, 2026, restricting trading to once a week due to a price variation exceeding 25% over five trading sessions (>30% over six), amid a stayed NCLT insolvency admission order related to a ₹370 crore contingent exposure as guarantor for unrelated Sinnar Thermal Power Limited, with NCLAT next hearing on April 17, 2026. The company remains operationally unaffected and financially sound with no CIRP or debt obligations. Q4 FY26 pre-sales reached a record ₹2,632 crore (+89% QoQ), FY26 pre-sales ₹4,631 crore (+128% YoY), Q4 collections ₹577 crore (+39% QoQ), and FY26 collections ₹1,721 crore.
- ·NCLAT granted stay on NCLT CIRP admission order dated December 9, 2025, via order dated December 11, 2025; stay remains in force
- ·NCLAT hearing on April 10, 2026 adjourned to April 17, 2026 with no further adjournments allowed
- ·Shares previously under Additional Surveillance Measure (ASM) due to NCLT order; now moved from IBC Stage 0 to IBC Stage 1
- ·Company confirms no debt-obligation; exposure relates only to contingent equity infusion as secondary obligor, deemed not financial debt by NCLT
- ·RERA registration obtained for Embassy Serenity, Alibaug (Phase I)
10-04-2026
Supha Pharmachem Limited (formerly Remedium Lifecare Limited) disclosed its list of creditors under Regulation 13(2)(c) of IBBI Regulations as part of the ongoing Corporate Insolvency Resolution Process (CIRP) commenced on March 17, 2026, with total claims received amounting to ₹1,237,511,620, of which only ₹821,735,148 admitted while ₹411,931,472 remain under verification or not admitted. Significant claims include ₹233,876,430 from government dues (₹230,031,430 admitted) and ₹673,271,198 from other operational creditors (₹591,703,718 admitted, ₹81,567,480 not admitted). The suspended directors have not cooperated in handing over control, records, or information to the Interim Resolution Professional (IRP) Rajesh Jhunjhunwala, with the first Committee of Creditors (CoC) meeting scheduled for April 14, 2026.
- ·CIRP commenced pursuant to NCLT Mumbai Bench order dated March 17, 2026 in C.P. (IB)/579/MB/2025.
- ·List of creditors prepared as on April 6, 2026.
- ·Powers of Board of Directors suspended under Section 17(1)(b) of Insolvency and Bankruptcy Code, 2016.
- ·IRP IP Registration Number: IBBI/IPA-003/IP-N00457-C01/2017-2018/11102.
10-04-2026
Future Enterprises Limited, under Corporate Insolvency Resolution Process, has intimated stock exchanges about the Forty-First meeting of the Committee of Creditors scheduled for Monday, 13 April 2026 at 04:30 P.M. The notice is issued by Resolution Professional Avil Menezes pursuant to SEBI LODR Regulation 30. No financial performance metrics, comparisons, or other operational updates are disclosed in this filing.
- ·BSE Scrip Code: 523574/570002; NSE Symbol: FEL/FELDVR
- ·RP Registration No: IBBI/IPA-001/IP-P00017/2016-17/10041
- ·Authorization for Assignment valid till 30th June 2027
10-04-2026
TVS Holdings Limited issued a clarification on April 10, 2026, correcting the date of the NCLT-convened meeting of Equity Shareholders from the inadvertently mentioned Friday, 28th April 2026 to the correct date of Friday, 24th April 2026. The meeting was directed by the Hon'ble National Company Law Tribunal, Chennai Bench on 18th March 2026, as referenced in the company's letter dated 23rd March 2026. All other documents, including the notice, XBRL filings, and newspaper advertisements, correctly stated the meeting date as 24th April 2026.
- ·NCLT Chennai Bench directions dated 18th March 2026
- ·Original letter dated 23rd March 2026 with error in covering letter only
- ·XBRL filings and newspaper advertisements correctly showed 24th April 2026
10-04-2026
Gabriel India Limited disclosed newspaper advertisements published on April 10, 2026, in Business Standard (English) and Navshakti (Marathi) regarding the final hearing of a composite Scheme of Arrangement before the NCLT Mumbai. The scheme involves the amalgamation of Anchemco India Private Limited (formerly Andasia Private Limited) into Asia Investments Private Limited (Part C) and the demerger of a undertaking from Asia Investments Private Limited into Gabriel India Limited (Part D), pursuant to an NCLT order dated March 24, 2026. This intimation complies with Regulation 30 of SEBI LODR Regulations, 2015.
- ·Advertisements relate to joint Company Petition under Sections 230-232 of Companies Act, 2013.
- ·NCLT Mumbai order directing advertisements: March 24, 2026.
- ·Company codes: BSE (505714), NSE (GABRIEL).
10-04-2026
MEP Infrastructure Developers Limited, under Corporate Insolvency Resolution Process (CIRP) pursuant to NCLT order dated March 28, 2024, with a moratorium in effect since then, held its 22nd Committee of Creditors meeting on April 9, 2026. Mr. Ravindra Kumar Goyal (IBBI/IPA-001/IP-P-02019/2020-2021/13098) serves as the Resolution Professional. This post-facto intimation under Regulation 30 of SEBI LODR discloses no specific meeting outcomes, highlighting the ongoing insolvency proceedings with no positive financial developments reported.
- ·Prior intimation letters dated April 2, 2024 and April 3, 2024 regarding CIRP commencement.
- ·Scrip Symbol: MEP; Security Code: 539126
10-04-2026
Kopran Limited announced that the NCLT Mumbai Bench, via order dated April 09, 2026, has directed the holding of meetings for Equity Shareholders, Secured Creditors, and Unsecured Creditors to approve the Scheme of Amalgamation (Merger by Absorption) of Kopran Laboratories Limited (Transferor) with Kopran Limited (Transferee). This update references the company's prior letter dated March 20, 2025, and complies with Regulation 30 of SEBI LODR. The NCLT order is available on the company's website.
- ·NCLT Mumbai Bench order dated April 09, 2026
- ·Previous reference letter dated March 20, 2025
- ·Order available at: https://www.kopran.com/wp-content/uploads/2026/04/Application-admission-Order-dated-09.04.2026-Kopran-Limited.pdf
- ·Disclosure under Regulation 30 of SEBI (LODR) Regulations
10-04-2026
On April 8, 2026, the NCLT ordered the replacement of Educomp Solutions Limited's Caretaker Resolution Professional, Mr. Mahender Kumar Khandelwal, with Mr. Kamal Kumar Jadwani as the new Resolution Professional to oversee the ongoing Corporate Insolvency Resolution Process (CIRP). In the absence of a Board, Mr. Jadwani will manage all company affairs. The company is awaiting the formal order copy and has referenced prior communications dated March 18 and March 23, 2026.
- ·NCLT Script Codes: BSE 532696, NSE EDUCOMP
- ·Company CIN: L74999DL1994PLC061353
- ·RP Registration: IBBI/IPA-001/IP-P00033/2016-17/10086
Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 8 filings
🇮🇳 More from India
View all →April 03, 2026
India Pre-Market Regulatory Roundup — April 03, 2026
India Pre-Market Regulatory Roundup
April 03, 2026
India Quarterly Results BSE NSE Announcements — April 03, 2026
India Quarterly Results BSE NSE Announcements
April 03, 2026
India Upcoming Corporate Actions BSE NSE — April 03, 2026
India Upcoming Corporate Actions BSE NSE
April 03, 2026
India RBI Banking Regulatory Enforcement Actions — April 03, 2026
India RBI Banking Regulatory Enforcement Actions